# Shaily Engineering Plastics (SHAILY)

CMP: ₹ 1808

Target: ₹ 2110 (17%)

Target Period: 12 months

August 19, 2021

# Ramp up of new products drives topline...

**About the stock:** Shaily Engineering is into manufacturing high precision injection moulded plastic components and finished goods in home furnishing, healthcare, toys, personal care, automotive components.

- Export revenue contributed ~74% to the topline in FY21 while rest came from domestic business for Shaily
- The company's biggest clients include a Swedish furnishing major, which contributes ~55% to the topline

Q1FY22 Results: Shaily posted strong revenue growth, crossing pre-Covid levels.

- Revenue grew 158% YoY to ₹ 120 crore, favoured by a lower base and ramp up of new products
- Higher operating leverage helped drive EBITDA margin up by ~843 bps YoY
- PAT came in at ₹ 8 crore vs. loss of ₹ 3 crore in the base period

What should investors do? Shaily Engineering's share price has grown by ~3.3x over five years (from ~₹ 510 in August 2016 to ~₹ 1790 level in July 2021).

We maintain our BUY rating on the stock

Target Price & valuation: We value Shaily at ₹ 2110 i.e. 32x on FY23E EPS.

#### Key triggers for future price performance:

- The company envisaged ~₹ 260 crore of capex plans for FY22E-24E to ramp up capacity in toys, healthcare and home furnishings
- New client additions will help drive healthcare segment revenue to 2-3x in the next three to five years. The company has added two new clients in the toy segment (Spin Master, Hasbro)
- Incremental sales of high margin products (like healthcare) will help drive EBITDA margin for the company

Alternate Stock Idea: We like MoldTek Packaging in the packaging space.

- Strong volume growth of  $\sim$ 20% in FY21-23E led by capacity expansion and client additions in the high margin product categories
- BUY with a target price of ₹ 675



BUY



Particulars	
Particular	Amount
Market Cap (₹ Crore)	1,504.0
Total Debt (FY21) (₹ Crore)	173.2
Cash & Inv (FY21) (₹ Crore)	2.9
EV (₹ Crore)	1,674.3
52 week H/L	1858/547
Equity capital (FY21) (₹ Crore)	8.3
Face value (₹)	10.0

Shareholding pattern											
(in %)	Jun-20	Sep-20	Dec-20	Mar-21	Jun-21						
Promoter	51.1	51.1	51.1	51.1	51.1						
FII	0.0	0.0	0.0	0.0	0.1						
DII	14.1	13.9	13.9	13.9	13.7						
Others	34.8	35.0	35.0	35.0	35.1						



### Recent event & key risks

 Key Risk: (i) Delay in order execution (ii) Delay in passing on high input prices

### **Research Analyst**

Sanjay Manyal sanjay.manyal@icicisecurities.com

Hitesh Taunk hitesh.taunk@icicisecurities.com

Key Financial Summary							
(₹ Crore)	FY19	FY20	FY21	5 Year CAGR (FY16-21)	FY22E	FY23E	2 Year CAGR (FY21-23)
Net Sales	338.3	336.0	360.6	10%	513.9	603.2	29%
EBITDA	52.6	58.1	59.6	9%	88.5	108.7	23%
EBITDA Margin (%)	15.6	17.3	16.5		17.2	18.0	
Reported PAT	19.3	23.6	22.0	9%	43.8	60.2	65%
EPS (₹)	23.2	28.4	26.5		47.7	65.7	
P/E	78.0	63.7	68.3		37.9	27.5	
P/BV (x)	11.0	9.4	8.3		4.5	3.9	
Mcap/Sales (x)	4.4	4.5	4.2		2.9	2.5	
RoCE (%)	16.2	14.2	11.6		13.4	16.7	
RoNW (%)	14.2	14.8	12.1		11.8	14.1	

Source: Company, ICICI Direct Research

## Key takeaways of recent quarter & conference call highlights

#### Q1FY22 Results:

- Strong topline growth in Q1FY22 is attributable to ramp up of new products (toys, carbon steel products). The plant utilisation was at 59% in Q1FY22.
   The management expects a further increase in plant utilisation led by order execution in toy, healthcare and home furnishing segments
- Gross margin was down ~110 bps YoY, mainly due to a delay in passing on
  of raw material prices. However, EBITDA margins increased to ~16% in
  Q1FY22 vs. 7.3% in Q1FY21. The management has further guided at passing
  on of raw material price in coming quarters, which will help in a recovery in
  gross margins
- It reported PAT of ₹ 8 crore in Q1FY22 vs. loss of ₹ 3 crore in base period

#### Q1FY22 Earnings Conference Call highlights

#### Future demand outlook and guidance:

- The management expects an uptick in revenue aided by new business confirmations, addition of new clients and increased contribution from new business segment
- The company expects 2-3x revenue growth from the healthcare segment on back of faster penetration within existing and new clients as well as a large pipeline of products
- The management has indicated at sustainable and normalised EBITDA margins on an annual basis on the back of higher utilisations of existing facilities and increasing contribution from the healthcare segment
- Shaily has secured two new contracts for pen injectors in healthcare
- The company expects an increase in profitability augmented by faster capacity utilisation in the carbon steel and healthcare business

#### Capex:

- o Expected capex for FY22 is ~₹ 80-85 crore
- Additional capex of ₹ 200 crore in FY23-24 to enhance the capacity of toy, healthcare and furnishing business
- Announced fund raising of ₹ 150 crore by issuing 8,55,072 fresh equity
- Utilisation is expected to increase in Q2FY22
- Peak revenue from current gross block is ~₹ 650 crore
- The company is seeking more clarity on export incentives under Remission of Duties and Taxes on Exported Products (RoDTEP) for export of plastic products

Exhibit 1: Peer Comparison																			
Sector / Company	CMP	TP Rating		Мсар	p Sales growth (%)			EBITDA mar (%)		EV/EBITDA (x)			RoCE (%)			RoE (%	)		
Sector / Company	(₹)	(₹)	nauliy	(₹ cr)	FY21	FY22E	FY23E	FY21	FY22E	FY23E	FY21	FY22E	FY23E	FY21	FY22E	FY23E	FY21	FY22E	FY23E
EPL Ltd (ESSPRO)	227	275	Hold	7,157	12.0	10.2	11.2	19.8	19.7	21.0	12.1	10.9	9.0	16.2	17.7	20.8	14.8	16.6	18.9
Mold Tek Pack (MOLPAC)	490	675	Buy	1,359	9.0	30.0	15.0	19.7	19.1	21.0	15.4	12.1	9.3	21.0	25.0	29.0	21.0	22.0	24.0
Time Tech (TIMTEC)	72	100	Buy	1,639	-16.0	21.4	12.4	12.9	13.6	14.2	6.5	5.2	4.4	8.7	12.2	13.9	5.7	9.5	11.3
Shaily Engi (SHAILY)	1,808	2,110	Buy	1,504	7.0	43.0	17.0	16.5	17.2	18.0	28.1	17.2	14.1	11.6	13.4	16.7	12.1	11.8	14.1

Source: Company, ICICI Direct Research

Shaily sees multi-fold revenue growth in the healthcare and toy business in the next four to five years. Hence, the company has decided to increase the manufacturing capacity of toys, healthcare and home furnishing products by infusing fresh equity of ₹ 150 crore. We build in revenue, PAT CAGR of 29% and 65%, respectively, in FY21-23E led by execution of new orders. Further, strong earnings growth and repayment of debt will lead to improve RoCE and RoE of the Shaily, going forward. We continue to maintain our BUY rating on the stock with a revised target price of ₹ 2110, valuing the company at 32x FY23 earnings.

	Q1FY22	Q1FY21	YoY (%)	Q4FY21	QoQ (%)	Comments
Revenue	120.1	46.6	157.7	109.8	9.4	Strong revenue growth with execution of new orders in the toy and home furnishing segments
Other Income	1.2	0.0	2787.9	2.4	-48	
Raw Material Exp	73.1	27.9	162.5	63.2	15.8	Delay in passing on of higher raw material prices led to drop in gross margin by $\sim$ 110 bps YoY (334 bps QoQ)
Employee Exp	10.4	7.0	47.7	10.1	2.7	
Power & Fuel	5.7	2.7	107.9	5.3	8.0	
Other Expenses	12.0	5.6	115.0	11.5	3.8	
Gross margin	39.1	40.2	-111 bps	42.4	-334 bps	
EBITDA	18.9	3.4	453.8	19.7	-3.8	
EBITDA Margin (%	15.8	7.3	843 bps	17.9	-217 bps	Cost optimisation measures partially negated the impact of lower gross margins $\text{QoQ}$
Depreciation	5.9	4.5	31.5	5.6	5.5	
Interest	3.6	3.0	23.3	3.3	10.6	Elevated debt level led to higher interest outgo
PBT	10.6	-4.0	LP	13.2	-19.4	
Total Tax	2.6	-1.0	NM	3.5	-24.6	
PAT	8.0	-3.0	LP	9.7	-17.5	Strong sales recovery helped drive bottomline
Key Metrics						
Volume	4093.0	1815.0	125.5	4356.0	-6.0	Lower base and improved utilisation of new capacities helped drive volume growth on a YoY basis

Source: Company, ICICI Direct Research

xhibit 3: Change in estimates											
(₹ Crore)	FY22E			F	/23E		Comments				
	Old	New %	6 Change	Old	New %	Change					
Revenue	523.7	513.9	(1.9)	622.7	603.2	(3 1)	We tweak our estimate upward considering strong revenue growth in Q1FY22				
EBITDA	91.5	88.5	(3.3)	112.2	108.7	(3.1)					
EBITDA Mar(%)	17.5	17.2	-25bps	18.0	18.0		We slightly tweak our EBITDA margin estimates for FY22 considering low operating leverage of new plants				
PAT	45.6	43.8	(4.0)	60.4	60.2	(0.3)					

Source: ICICI Direct Research

# Financial Summary

Exhibit 4: Profit and loss sta	₹	₹ crore		
(Year -End -March)	FY20	FY21	FY22E	FY23E
Net sales	336.0	360.6	513.9	603.2
Growth (%)		7	43	17
Expenses				
Raw Material Expenses	197.9	215.3	310.4	359.4
Employee Expenses	26.0	34.2	41.2	48.3
Power & Fuel cost	17.4	17.9	23.8	30.2
Other Expenses	36.7	33.6	50.0	56.7
Total Operating Expenditure	277.9	301.0	425.4	494.5
EBITDA	58.1	59.6	88.5	108.7
Growth (%)	49.0	2	49	23
Other Income	1.0	2.6	3.2	4.0
Depreciation	17.9	19.5	21.7	24.1
Interest	10.5	12.7	11.7	8.3
PBT before Exc. Items	30.7	29.9	58.3	80.3
Less: Exc. Items	0.0	0.0	0.0	0.0
PBT after Exc. Items	30.7	29.9	58.3	80.3
Total Tax	7.1	7.9	14.5	20.1
Adjusted PAT	23.6	22.0	43.8	60.2

Source: Company, ICICI Direct Research

Exhibit 5: Cash flow statemer	nt		:	₹ crore
(Year -End -March)	FY20	FY21	FY22E	FY23E
Profit/(Loss) after taxation	23.6	22.0	43.8	60.2
Add: Depreciation & Amortization	17.9	19.5	21.7	24.1
Add: Interest Paid	10.5	12.7	11.7	8.3
Cash Flow before working capital cha	52.0	54.3	77.2	92.6
Net Increase in Current Assets	-19.6	-20.1	-57.2	-22.3
Net Increase in Current Liabilities	23.3	7.6	50.8	31.9
Net cash flow from operating activitie	55.7	41.7	70.9	102.1
Cash flow from Investing Activities				
(Purchase)/Sale of Fixed Assets	-71.0	-73.7	-85.0	-100.0
Others	9.0	-12.5	29.1	-1.0
Net Cash flow from Investing Activiti	-62.0	-86.2	-55.9	-101.0
Cash flow from Financing Activities				
(Payment) of Dividend and Dividend 1	-3.3	0.0	0.0	-1.2
Interest Paid	-10.5	-12.7	-11.7	-8.3
Others	27.4	51.0	113.8	-50.0
Net Cash flow from Financing Activit	13.6	38.3	102.1	-59.5
Net Cash flow	7.2	-6.2	117.0	-58.3
Cash and Cash Equivalent at the beginner	1.9	9.1	2.9	119.9
Cash and Cash Equivalent at the end	9.1	2.9	119.9	61.6

Source: Company, ICICI Direct Research

Exhibit 6: Balance Sheet				₹ crore
(Year -End -March)	FY20	FY21	FY22E	FY23E
Equity Capital	8.3	8.3	9.2	9.2
Reserve and Surplus	151.1	173.5	360.2	419.3
Total Shareholders funds	159.4	181.9	369.4	428.5
Total Debt	122.7	173.2	143.2	93.2
Deferred Tax Liability	7.3	10.3	10.3	10.3
Other Non Current Liabilities	0.0	2.5	0.0	0.0
Others Total	7.3	12.7	10.3	10.3
Total Liability	289.4	367.8	522.9	532.0
Gross Block	226.4	300.1	385.1	485.1
Accumulated Depreciation	60.6	80.1	101.8	125.9
Net Block	165.8	220.0	283.3	359.3
Capital WIP	37.2	37.2	37.2	37.2
Total Fixed Assets	203.0	257.2	320.5	396.4
Liquid Investments	0.3	0.0	1.0	2.0
Current Asset				
Inventory	49.7	66.9	84.5	90.9
Debtors	61.0	69.5	92.9	107.4
Loans and Advances	14.3	0.7	1.0	1.2
Cash	9.1	2.9	119.9	61.6
Total Current Assets	163.4	177.3	351.5	315.4
Current Liability				
Creditors	51.2	46.6	74.6	90.9
Provisions	2.1	2.4	3.9	4.7
Total Current Liabilities	91.6	99.2	150.0	181.9
Net Current Assets	71.8	78.1	201.4	133.5
Other Assets	14.3	32.5	0.0	0.0
Total Asset	289.4	367.8	522.9	532.0

Source: Company, ICICI Direct Research

Exhibit 7: Key ratios	;			
(Year -End -March)	FY20	FY21	FY22E	FY23E
Per Share Ratio				
EPS	28.4	26.5	47.7	65.7
Cash EPS	49.9	49.9	71.3	91.9
DPS	4.0	0.0	0.0	1.3
BV	191.6	218.6	402.7	467.1
Operating ratio				
EBITDA Margin	17.3	16.5	17.2	18.0
PAT Margin	7.0	6.1	8.5	10.0
Return Ratios				
RoCE	14.2	11.6	13.4	16.7
RoE	14.8	12.1	11.8	14.1
RoIC	15.1	11.6	15.3	16.4
Valuatin Ratios				
EV / EBITDA	27.8	28.1	17.2	14.1
P/E	63.7	68.3	37.9	27.5
EV/Net Sales	4.8	4.6	3.0	2.5
Mcap/sales	4.5	4.2	2.9	2.5
P/BV	9.4	8.3	4.5	3.9
Turnover Ratios				
Gross Block turnover	1.5	1.2	1.3	1.2
Inventory Days	54.0	67.7	60.0	55.0
Debtor Days	66.3	70.4	66.0	65.0
Creditor Days	55.6	47.2	53.0	55.0
Solvency Ratios				
Debt/Equity	0.8	1.0	0.4	0.2
Debt/Ebitda	2.1	2.9	1.6	0.9
Current Ratio	2.9	3.6	2.9	2.7
Quick Ratio	2.0	2.2	1.9	1.7

Source: Company, ICICI Direct Research

## **RATING RATIONALE**

ICICI Direct endeavors to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according -to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head - Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com

#### ANALYST CERTIFICATION

I/We, Sanjay Manyal (MBA Finance), Hitesh Taunk (MBA Finance) Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

#### Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavor to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.